Archives of Cardiovascular Diseases最新文献

{"title":"Referral for heart transplantation and combined heart-liver transplantation in a contemporary cohort of adults with congenital heart disease","authors":"Estíbaliz Valdeolmillos ,&nbsp;Belli Emre ,&nbsp;Ilias Kounis ,&nbsp;Chady Salloum ,&nbsp;Julien Guihaire ,&nbsp;Joy Zoghbi ,&nbsp;Régine Roussin ,&nbsp;Sébastien Hascoët ,&nbsp;David Blanchard ,&nbsp;Martin Kloeckner ,&nbsp;Daniel Azoulay ,&nbsp;Daniel Cherqui ,&nbsp;Audrey Coilly ,&nbsp;Sarah Cohen","doi":"10.1016/j.acvd.2025.06.010","DOIUrl":"10.1016/j.acvd.2025.06.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Adults with congenital heart disease (ACHD) may develop advanced heart failure with associated liver disease from chronic right-sided heart or Fontan failure. Thus, CHD with subsequent irreversible liver dysfunction is an increasing indication for combined heart-liver transplant (CHLT). A systematic liver function assessment is therefore essential prior to listing for heart transplantation (HTx). We aimed to describe clinical characteristics, underlying cardiac defects, surgical history, perioperative issues, and outcomes in a contemporary cohort of ACHD referred for HTx or CHLT.</div></div><div><h3>Method</h3><div>We prospectively included all ACHD patients referred to our centre for HTx between August 2021 and February 2025. Liver function and disease were evaluated systematically before listing. Inclusions criteria were 1) CHD; 2) HT/CHLT referral; and 3) age<!--> <!-->&gt;<!--> <!-->18 years at the time of referral.</div></div><div><h3>Results</h3><div>A total of 22 ACHD patients were referred for HT/CHLT to our centre between August 2021 and February 2025. Mean age at referral was 36<!--> <!-->±<!--> <!-->24 years. Twelve patients (55%) had univentricular physiology, and all were in New York Heart Association (NYHA) functional class III or IV at the time of referral. Following initial evaluation, 5 patients were listed for CHLT, 7 patients for HTx (including 1 for combined heart-kidney transplantation). The main indications for CHLT were hepatocellular carcinoma and refractory ascites. Three patients died before listing, one of whom received Carmat artificial heart. Prior to transplantation, two patients required inotropic support, two were supported with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) (<span><span>Figure 1</span></span>). The median time from evaluation to listing or death prior to listing was 146 days (IQR 28–598 days). Among listed patients, the median time from listing to transplantation or death was 150 days (IQR 55–210 days). Among the 9 transplanted patients, no one died during the study period. No patients required VA-ECMO after transplantation, and no major post-transplant complications were reported.</div></div><div><h3>Conclusion</h3><div>In this contemporary cohort, patients with HF referred for HT/CHLT are heterogeneous also in terms of severity. Results after CHLT in our Centre are encouraging. Times from evaluation to listing and to transplantation are long. This supports the importance of early referral.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S252"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial work during various right ventricle load conditions in pediatric congenital heart disease","authors":"Ramona Ghenghea ,&nbsp;Hadeed Khaled ,&nbsp;Philippe Acar ,&nbsp;Pierrick Pyra ,&nbsp;Aitor Guitarte ,&nbsp;Paul Vignaud ,&nbsp;Yves Dulac ,&nbsp;Clement Karsenty","doi":"10.1016/j.acvd.2025.06.062","DOIUrl":"10.1016/j.acvd.2025.06.062","url":null,"abstract":"<div><h3>Introduction</h3><div>Assessing right ventricular (RV) function in pediatric population is challenging, especially with RV overload. Traditional echocardiography doesn’t account for afterload, limiting accuracy. This study aimed to assess RV myocardial work (RVMW), a method integrating contractile function and afterload, in children with varying RV load conditions.</div></div><div><h3>Method</h3><div>This prospective single center study was conducted from March 2023 to March 2024. A total of 35 children were divided into two groups: 18 with volume overload (pre-tricuspid shunts) and 17 with pressure overload group (precapillary pulmonary arterial hypertension). A control group of 17 healthy children was included. All subjects underwent 2D and 3D transthoracic echocardiography (TTE) to assess RV volumes and function. RVMW was derived from the pressure-strain relationship incorporating pulmonary artery pressures and RV strain (<span><span>Figure 1</span></span>).</div></div><div><h3>Results</h3><div>Both overload groups showed RV enlargement (95<!--> <!-->±<!--> <!-->24<!--> <!-->ml/m² in the pressure overload group and 119<!--> <!-->±<!--> <!-->25<!--> <!-->ml/m² in the volume overload group versus 53<!--> <!-->±<!--> <!-->14<!--> <!-->ml/m² in the control group), without significant differences in RV volume between them (<em>p</em> <!-->=<!--> <!-->0.26). Traditional echocardiographic parameters indicated normal RV longitudinal function, but RV free wall strain (FWS) was lower in the pression overload group compared to the volume overload group (−23.4<!--> <!-->±<!--> <!-->5.2 <em>vs.</em> −31.3<!--> <!-->±<!--> <!-->4.5%, <em>p</em> <!-->&lt;<!--> <!-->0.001). RVMW indices, including RV global work index (GWI), global contractile work (GCW), were higher in the pressure overload group compared to the volume overload group (823<!--> <!-->±<!--> <!-->278 <em>vs.</em> 468<!--> <!-->±<!--> <!-->81 and 1083<!--> <!-->±<!--> <!-->405 <em>vs.</em> 586<!--> <!-->±<!--> <!-->77mmHg%, <em>p</em> <!-->=<!--> <!-->0.0007 and <em>p</em> <!-->&lt;<!--> <!-->0.0001 respectively). GWI and GCW were negatively correlated with TAPSE/PAPS (r<!--> <!-->=<!--> <!-->−0.81 and r<!--> <!-->=<!--> <!-->−0.80; <em>p</em> <!-->&lt;<!--> <!-->0.001) and with pulmonary VTI/PAPS (r<!--> <!-->=<!--> <!-->−0.75 and 0.75; <em>p</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>The assessment of RVMW is feasible in children with RV hemodynamic overload and shows differences compared to healthy controls. In this study, we offer evidence that expands the use of RVMW to children with different types of RV hemodynamic overload, including pressure and volume overload. While MW holds significant potential and is gaining increasing attention, larger studies are necessary to fully define its role and integration into routine clinical practice.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S281"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement in patients with degenerated aortic bioprostheses: Three-year death rates and haemodynamic performance","authors":"Grégoire Rosier ,&nbsp;Guillaume Guimbretière ,&nbsp;Patrice Guérin ,&nbsp;Claire Bouquin ,&nbsp;Stéphane Delépine ,&nbsp;Frédéric Pinaud ,&nbsp;Frédéric Rouleau ,&nbsp;Thomas Sénage ,&nbsp;Jean Christian Roussel ,&nbsp;Jérémie Riou ,&nbsp;Thierry Le Tourneau ,&nbsp;Loïc Bière","doi":"10.1016/j.acvd.2025.03.124","DOIUrl":"10.1016/j.acvd.2025.03.124","url":null,"abstract":"<div><h3>Background</h3><div>Management of degenerated aortic bioprostheses through valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) or redo surgical aortic valve replacement (Re-SAVR) shows similar short-term safety and efficacy. However, long-term survival and haemodynamic performance data are limited.</div></div><div><h3>Aim</h3><div>To compare clinical characteristics, haemodynamics and outcomes at 3 years between ViV-TAVR and Re-SAVR techniques.</div></div><div><h3>Methods</h3><div>This retrospective two-centre study included 266 patients treated for isolated aortic bioprosthesis degeneration (130 Re-SAVR, 136ViV-TAVR) from 2009 to 2018, with up to 3 years of follow-up.</div></div><div><h3>Results</h3><div>The ViV-TAVR group was older (83 vs. 77 years; <em>P</em> <!-->=<!--> <!-->0.005) with higher surgical risk (Logistic EuroSCORE 22% vs. 13%; <em>P</em> <!-->=<!--> <!-->0.005). At 3 years, univariate analysis showed no significant difference in all-cause deaths (22.1% vs. 17.7%; <em>P</em> <!-->=<!--> <!-->0.37). ViV-TAVR was associated with fewer first-month complications, including major bleeding (11.0% vs. 52.3%; <em>P</em> <!-->=<!--> <!-->0.007) and acute renal failure grade 2/3 (5.1% vs. 14.6%; <em>P</em> <!-->=<!--> <!-->0.053). Inverse probability of treatment weighting analysis revealed no difference in all-cause deaths at 1 year (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.36–1.67; <em>P</em> <!-->=<!--> <!-->0.52) or between 1 and 3 years (HR 1.56, 95% CI 0.82–2.99; <em>P</em> <!-->=<!--> <!-->0.17). Composite events were similar at 1 year (HR 0.80, 95% CI 0.44–1.44; <em>P</em> <!-->=<!--> <!-->0.45) and between 1 and 3 years (HR 1.41, 95% CI 0.83–2.38; <em>P</em> <!-->=<!--> <!-->0.21). Mean gradients at 3 years were similar (16.1<!--> <!-->±<!--> <!-->11.4 vs. 13.2<!--> <!-->±<!--> <!-->5.3<!--> <!-->mmHg; <em>P</em> <!-->=<!--> <!-->0.17). In patients with small bioprostheses (true internal diameter<!--> <!-->≤<!--> <!-->20<!--> <!-->mm [<em>n</em> <!-->=<!--> <!-->151]), death rates at 3 years were similar (21.1% vs. 20.0%; <em>P</em> <!-->=<!--> <!-->0.86), as was haemodynamic performance (mean gradient 19.2<!--> <!-->±<!--> <!-->14.0<!--> <!-->mmHg for ViV-TAVR vs. 13.7<!--> <!-->±<!--> <!-->4.12<!--> <!-->mmHg for Re-SAVR [<em>P</em> <!-->=<!--> <!-->0.38]). Compared to balloon-expandable, self-expandable valves showed better 1-year mean gradients (16.4<!--> <!-->±<!--> <!-->10.5 vs. 13.7<!--> <!-->±<!--> <!-->4.12<!--> <!-->mmHg; <em>P</em> <!-->=<!--> <!-->0.012).</div></div><div><h3>Conclusions</h3><div>ViV-TAVR and Re-SAVR had similar mortality and haemodynamic outcomes at 3 years, including in patients with small bioprostheses where self-expandable valves yielded the best results.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Pages 464-476"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of a two year educational prevention program","authors":"Lisa Guirgis,&nbsp;Ghita Afilal,&nbsp;Estíbaliz Valdeolmillos,&nbsp;Nadera Chaouche,&nbsp;Sara Jemai,&nbsp;Alice Dirickx,&nbsp;Sarah Cohen,&nbsp;Sébastien Hascoët,&nbsp;Emmanuelle Fournier","doi":"10.1016/j.acvd.2025.06.021","DOIUrl":"10.1016/j.acvd.2025.06.021","url":null,"abstract":"<div><h3>Introduction</h3><div>The growing population of patients living with congenital heart disease (CHD) has led to an increased use of prosthetic material, placing many at high-risk for infective endocarditis (IE). To reduce this risk and its associated morbidity and mortality, we implemented an institutional educational prevention program (EPP). This study evaluated patient adherence to the program and outcomes after two years.</div></div><div><h3>Method</h3><div>This was a prospective, observational, and single-center study. Inclusion criteria comprised age<!--> <!-->&gt;<!--> <!-->10 years and high-risk for IE, defined by the presence of prosthetic material, chronic cyanosis and/or prior history of IE. The EPP included an initial individual consultation, followed by a full in-person day at our institution featuring age-specific group sessions. This one-day educational intervention focused on CHD understanding, IE prevention, dental and cutaneous care with tailored workshops and multidisciplinary team. Systematic follow-up was conducted at 6 months and 1 year.</div></div><div><h3>Results</h3><div>Between November 2022 and March 2025, 150 patients completed the initial step, and 112 (74.6%) attended the full program. Of these, 65% were male, with a median age of 21 years [7–75], median weight of 61<!--> <!-->kg [48–74], height of 164<!--> <!-->cm [155–174], and BMI of 21<!--> <!-->kg.m2 [18–25]. CHD severity was classified in simple (14.2%), moderate (46.4%), or complex (33.9%). Risk factors for IE included prosthetic material (n<!--> <!-->=<!--> <!-->101), a history of prior IE (n<!--> <!-->=<!--> <!-->11), and Eisenmenger syndrome (n<!--> <!-->=<!--> <!-->4). The median time since the last cardiac surgery was 5.6 years [1.7–23.4]. The median time since the last catheterization was 2.2 years [1.4–13.8]. Prosthetic material, defined as bioprothesis, conduit, or mechanical valve, was located on the right side in 72.3% of patients, the left side in 7.1%, and on both sides in 7.1%. The median follow-up duration after EPP participation was 1.2 years [0.8–1.8]. No cases of IE or deaths were reported. Patient satisfaction was consistently high, attributed to the dedicated time for interaction and collaboration among patients, multidisciplinary specialists, and the presence of patient association.</div></div><div><h3>Conclusion</h3><div>The EPP showed high level of adherence and acceptability among participants. Although follow-up duration is currently limited, the absence of IE to date suggests a potential beneficial effect on IE prevention in high-risk CHD patients. Ongoing mid- and long-term follow-up will be essential to confirm sustained benefits and outcomes.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S258"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary hypertension associated with congenital heart disease: Evolution and prognostic factors from the ITINERAIR registry","authors":"Tarcile Albaret ,&nbsp;Cohen Sarah ,&nbsp;Sébastien Hascoët ,&nbsp;Xavier Iriart ,&nbsp;Claire Dauphin ,&nbsp;Ali Houeijeh ,&nbsp;Laurianne Le Gloan ,&nbsp;Pamela Moceri ,&nbsp;Fanny Dion ,&nbsp;Yves Dulac ,&nbsp;Hugues Lucron ,&nbsp;Quentin Hauet ,&nbsp;Pascal Amédro ,&nbsp;Caroline Ovaert ,&nbsp;Laurent Bonnemains ,&nbsp;Pascale Maragnes ,&nbsp;Hélène Bouvaist ,&nbsp;Laurence Iserin ,&nbsp;Damien Bonnet ,&nbsp;Mathieu Albertini","doi":"10.1016/j.acvd.2025.06.033","DOIUrl":"10.1016/j.acvd.2025.06.033","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with congenital heart disease are increasingly reaching adulthood, suggesting a growing exposure to complications, including pulmonary hypertension. Despite improved management, the onset of pulmonary hypertension is a turning point in the evolution of the disease and threatens the prognosis of patients.</div></div><div><h3>Method</h3><div>This is a prospective, multicenter cohort study from the ITINERAIR registry including children and adults with congenital heart disease and pulmonary hypertension followed from January 2014 to December 2018.</div><div>We classified patients into three groups according to the existence of a shunt, whether corrected or persistent, with or without Eisenmenger syndrome, in order to identify prognostic factors for each.</div></div><div><h3>Results</h3><div>The prognostic factors for major events in our study were a history of right heart failure and saturation level. The specific risk of mortality or heart and/or lung transplantation is determined by right atrial pressure.</div></div><div><h3>Conclusion</h3><div>The prognosis of patients with congenital heart disease complicated by pulmonary hypertension can be assessed using simple tests. Cardiac catheterization appears to play an essential role in the evaluation of this population.</div><div>Further studies with longer follow-up are needed to confirm our findings and lead to recommendations specific to this patient population.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S265"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Libman-Sacks endocarditis in pediatric systemic lupus erythematosus: A multicenter retrospective study","authors":"Safia Essbai ,&nbsp;Maelle Selegny ,&nbsp;Berangere Urbina-Hiel ,&nbsp;Elise Barre ,&nbsp;Héloïse Reumaux ,&nbsp;Isabelle Durand ,&nbsp;Djamal-Dine Djeddi ,&nbsp;Elise Daire","doi":"10.1016/j.acvd.2025.06.029","DOIUrl":"10.1016/j.acvd.2025.06.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Libman-Sacks endocarditis in pediatric systemic lupus erythematosus: a multicenter retrospective study.</div></div><div><h3>Objective</h3><div>To estimate the prevalence of LSE in pediatric SLE, describe its clinical and embolic features, identify associated risk factors, and evaluate therapeutic approaches.</div></div><div><h3>Methods</h3><div>We will conduct a multicenter retrospective cohort study including pediatric SLE patients diagnosed between 2006 and 2024 in three French centers (Lille, Rouen, Amiens). A nested case-control analysis will compare patients with LSE (cases) to those without valvular involvement (controls), matched on age and disease duration when feasible. Data collection is ongoing and includes clinical, immunological, and echocardiographic data, embolic events, corticosteroid resistance, and treatments. Associations will be assessed using odds ratios (ORs) with 95% confidence intervals.</div></div><div><h3>Expected results</h3><div>Among the 30 patients currently included, 5 have confirmed LSE. We expect to identify potential factors associated with LES such as antiphospholipid antibodies, active disease, and corticosteroid resistance. Detailed descriptions of embolic complications and variability in therapeutic strategies are also anticipated.</div></div><div><h3>Perspectives</h3><div>This study aims to raise awareness of LSE as a rare but serious complication in pediatric SLE. It may help identify lupus patients at risk of developing LSE in the pediatric population, and clarify cardiac lesions, complications, and therapeutic strategies in these patients.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S262"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychoactive drug use and prognosis in patients with cancer presenting with acute cardiovascular disease","authors":"Maxime Jaëck ,&nbsp;Nathan El Bèze ,&nbsp;Jean-Guillaume Dillinger ,&nbsp;Antonin Trimaille ,&nbsp;Anne Solène Chaussade ,&nbsp;Christophe Thuaire ,&nbsp;Clément Delmas ,&nbsp;Albert Boccara ,&nbsp;Vincent Roule ,&nbsp;Damien Millischer ,&nbsp;Eugénie Thevenet ,&nbsp;Christophe Meune ,&nbsp;Mathilde Stevenard ,&nbsp;Laura Maitre Ballesteros ,&nbsp;Nissim Grinberg ,&nbsp;Trecy Gonçalves ,&nbsp;Mathilde Baudet ,&nbsp;Amine El Ouahidi ,&nbsp;Fédérico Swedsky ,&nbsp;Benoit Lattuca ,&nbsp;Clément Charbonnel","doi":"10.1016/j.acvd.2025.03.122","DOIUrl":"10.1016/j.acvd.2025.03.122","url":null,"abstract":"<div><h3>Background</h3><div>The psychoactive drug consumption and the short- and long-term cardiovascular prognosis of patients with cancer admitted for acute cardiovascular events are not well established.</div></div><div><h3>Aims</h3><div>To assess the prevalence of psychoactive drug use, in-hospital outcomes and 1-year prognosis in patients with cancer hospitalized for acute cardiovascular events.</div></div><div><h3>Methods</h3><div>In a prospective multicentre study of all consecutive patients admitted to intensive cardiac care units, a history of cancer was recorded systematically. The primary outcome was the prevalence of psychoactive drugs detected by urine drug assay. The secondary outcomes were: the rate of in-hospital major adverse events, defined as all-cause death, cardiogenic shock and cardiac arrest; and the 1-year rate of major adverse cardiovascular and cerebrovascular events, defined as cardiovascular death, myocardial infarction and stroke.</div></div><div><h3>Results</h3><div>Among 1499 patients recruited, 151 had a history of cancer (10%), including 61 (40%) with active cancer and 90 (60%) with cancer in remission. Among patients with a history of cancer, 39 (25.8%) tested positive for at least one psychoactive drug. Using a matching approach based on the likelihood of having a cancer, a history of cancer was not associated with an increased risk of in-hospital major adverse events (odds ratio: 1.54, 95% confidence interval: 0.68–3.45; <em>P</em> <!-->=<!--> <!-->0.3). However, a history of cancer was associated with a higher incidence of 1-year major adverse cardiovascular and cerebrovascular events (hazard ratio: 3.04, 95% confidence interval: 1.63–5.67; <em>P</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusions</h3><div>The prevalence of psychoactive drug use among patients with a history of cancer hospitalized for acute cardiovascular events was 25.8%. A history of cancer was an independent predictor of 1-year major adverse cardiovascular and cerebrovascular events.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Pages 446-456"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter in response to the article entitled “Reevaluating the role of left atrial strain in systemic cardiomyopathies: A call for nuanced metrics and broader inclusion” by Sharma et al.","authors":"Charles Massie","doi":"10.1016/j.acvd.2025.06.066","DOIUrl":"10.1016/j.acvd.2025.06.066","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page 509"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Ross Procedure Outcomes on the Aortic Root Before and After Age 16","authors":"Marien Lenoir ,&nbsp;Pierre Alessandro Galamini ,&nbsp;Virginie Fouilloux ,&nbsp;Celia Gran ,&nbsp;Bernard Kreitmann ,&nbsp;Loïc Mace ,&nbsp;Dominique Metras","doi":"10.1016/j.acvd.2025.06.051","DOIUrl":"10.1016/j.acvd.2025.06.051","url":null,"abstract":"<div><h3>Introduction</h3><div>To evaluate the long-term outcomes of the Ross/Ross-Konno procedure in patients under 16 years of age compared to those over 16, with a focus on the hemodynamic performance of the pulmonary autograft.</div></div><div><h3>Method</h3><div>A retrospective analysis was conducted on patients operated between 1992 and 2024. Data were collected from hospital records, with complete follow-up for 90% of patients (10% lost to follow-up abroad). Two groups were formed: children (0–16 years) and adults (&gt;<!--> <!-->16 years). The primary endpoint was survival.</div></div><div><h3>Results</h3><div>Among the 171 patients included, 83 were under 16 years old (median age: 8.5 years) and 88 were adults (median age: 26.4 years). Before surgery, 36.5% of children had aortic stenosis, 26.5% had regurgitation, and 37% had mixed disease, compared to 34%, 37.5%, and 28.5% respectively in adults. Early mortality was 3.6% in children and 1.1% in adults. Seven late deaths were recorded. Twenty-year survival was 87% in patients under 16 and 96% in adults (<em>P</em> <!-->=<!--> <!-->0.2) (<span><span>Figure 1</span></span>). Freedom from autograft reoperation at 20 years was 84% in children versus 82% in adults (<em>P</em> <!-->=<!--> <!-->0.67). However, reinterventions on the right ventricular outflow tract were more frequent in younger patients (47% <em>vs.</em> 82% at 20 years, <em>P</em> <!-->&lt;<!--> <!-->0.001). At the end of follow-up, the diameter of the sinus of Valsalva was 37.7<!--> <!-->±<!--> <!-->9<!--> <!-->mm in children compared to 39.7<!--> <!-->±<!--> <!-->7<!--> <!-->mm in adults.</div></div><div><h3>Conclusion</h3><div>The Ross procedure provides good autograft growth in younger patients, with performance comparable to adults. However, patients under 16 require more frequent reinterventions on the pulmonary homograft.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S275"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin in Adult Patients with Failing Fontan (DAPA-FONTAN): A Prospective Multicentre Study","authors":"Mathieu Albertini ,&nbsp;Victor Waldmann ,&nbsp;Valentin Baland ,&nbsp;Elise Barre ,&nbsp;Jelena Radojevic ,&nbsp;Laurianne Le Gloan ,&nbsp;Patrice Guérin ,&nbsp;Fabien Labombarda ,&nbsp;Fanny Dion ,&nbsp;Reaksmei Ly ,&nbsp;François Godart ,&nbsp;Pamela Moceri ,&nbsp;Pauline David ,&nbsp;Alexis Barat ,&nbsp;Antoine Legendre ,&nbsp;Anne-Solene Chaussade ,&nbsp;Sebastien Hascoet ,&nbsp;Laurence Iserin","doi":"10.1016/j.acvd.2025.06.009","DOIUrl":"10.1016/j.acvd.2025.06.009","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure (HF) is the leading cause of death in adults with congenital heart disease, particularly in patients with a univentricular heart and Fontan circulation. Over time, this circulation is associated with increasing morbidity, especially in cases of circulatory failure (Failing Fontan–FF). FF has multiple causes: systolic or diastolic dysfunction of the single ventricle, elevated pulmonary vascular resistance, significant valve regurgitation, or stenoses within the Fontan circuit. Therapeutic options are limited, and Dapagliflozin—currently recommended for left-sided HF—may offer functional benefits in this specific population.</div></div><div><h3>Objective</h3><div>To assess the impact of Dapagliflozin on functional capacity in adult patients with FF due to systolic or diastolic dysfunction.</div></div><div><h3>Methods</h3><div>A 6-month prospective, multicenter, observational study.<strong>Inclusion criteria</strong> include adults older than 18 years with FF confirmed by right heart catheterization within the past 6 months, defined by:</div><div>– Systolic dysfunction with single ventricular ejection fraction (EF)<!--> <!-->≤<!--> <!-->40% and ventricular end-diastolic pressure (VEDP) or pulmonary artery wedge pressure (PAWP)<!--> <!-->≥<!--> <!-->15<!--> <!-->mmHg.</div><div>– Diastolic dysfunction with EF<!--> <!-->≥<!--> <!-->41% and VEDP or PAWP<!--> <!-->≥<!--> <!-->15<!--> <!-->mmHg.<strong>Exclusion criteria</strong> include severe atrioventricular valve regurgitation, elevated pulmonary vascular resistance, Fontan circuit stenosis, pregnancy, eGFR<!--> <!-->&lt;<!--> <!-->25<!--> <!-->ml/min/1.73 m², and systolic BP<!--> <!-->&lt;<!--> <!-->95<!--> <!-->mmHg.<strong>Primary endpoint:</strong> Change in VO₂ max on cardiopulmonary exercise testing (CPET) between baseline and 6 months.<strong>Secondary endpoints:</strong> NYHA class, quality of life (KCCQ-12), NT-proBNP levels, EF, number of HF-related hospitalizations, diuretic dosage, liver and kidney function, blood pressure, and adverse events.</div></div><div><h3>Expected Results</h3><div>An improvement in exercise capacity, NYHA class, quality of life, and biological parameters is expected, with good clinical and biological tolerance of the treatment.</div></div><div><h3>Perspectives</h3><div>This study may support the targeted use of Dapagliflozin in FF patients with systolic or diastolic dysfunction and lay the groundwork for future randomized trials in this high-risk population.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Pages S251-S252"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}